ALCOA+ and Data Integrity

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2020
Volume 2020 eBook
Issue 1
Pages: 10-13

Data supporting the quality and safety of product must meet the ALCOA+ elements in order to avoid regulatory citations for data integrity issues.

Data supporting the quality and safety of product must meet the ALCOA+ elements in order to avoid regulatory citations for data integrity issues.

Read this article in Pharmaceutical Technology’s March 2020 Regulatory Sourcebook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2020
March 2020
Pages: 10–13

Citation

When referring to this article, please cite it as S. J. Schniepp, “ALCOA+ and Data Integrity," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2020).

 

 

Articles in this issue
Guidelines_225.jpg
Resources, Guidelines, and Guidance Documents
Orgs_225.jpg
Regulatory and Standard Setting Organizations
PTebook0320_004-005_RegulatoryActionUpdate_Peters.gif
A ‘New Normal’ for Quality?
Pharmacopoeia 1_225.jpg
Monograph Development: Why and When to Participate (eBook)
Pharmacopoeia 3_225.jpg
Pharmacopoeia Compliance: Putting It All Together; What Is on the Horizon (eBook)
Pharmacopoeia 2_225.jpg
A Practical Approach to Pharmacopoeia Compliance (eBook)
PTebook_cellandgene.jpg
Inside FDA’s New Gene and Cell Therapy Guidances
PT ebook_ALCOA.jpg
ALCOA+ and Data Integrity
Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content
Logo of Merck KgA, Merck is a German multinational science and technology company. | Image Credit: © Robert - stock.adobe.com

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery
June 10th 2025
Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

USP Opens Advanced Technology Lab in Maryland

Susan Haigney
June 4th 2025
Article

The new lab will be used to develop and scale innovations for the production of medicines and to help secure the supply chain.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Guidance on Quality Culture Standards

Matt Cushing;Susan J. Schniepp
June 3rd 2025
Article

Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.

Cambridge, MA, USA - June 29, 2022: Moderna logo is seen at the entrance to its headquarters in Cambridge, Massachusetts. Moderna, Inc., is an American pharmaceutical and biotechnology company. | Image Credit: © Tada Images - stock.adobe.com

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE

Patrick Lavery
June 2nd 2025
Article

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.